SCCM Account Access
SCCM recently updated its digital infrastructure. If you have an existing SCCM account, and have not logged in since November 1, 2024, you will need to create an account with the email address associated with your previous SCCM account. Learn more about SCCM account access here.
Some website functionality may be limited as improvements continue. Please ensure you are logged in for the best experience.
Guidelines for the Management of Adult Acute and Acute-on-Chronic Liver Failure (Part I)
Citation: Crit Care Med. 2020 March;48(3):415-419
Guideline Type: Clinical
Related Resources:
Liver Guidelines Recommendations Table
Guideline Section:
Strength:
We recommend against using hydroxyethyl starch for initial fluid resuscitation of patients with acute liver failure or acute on chronic liver failure.
Quality of Evidence: Moderate
We suggest against using gelatin solutions for initial fluid resuscitation of patients with acute liver failure or acute on chronic liver failure.
Quality of Evidence: Low
We suggest using albumin for resuscitation of patients with acute liver failure or acute on chronic liver failure over other fluids, especially when serum albumin is low (<3 mg/dL).
Quality of Evidence: Low
We suggest targeting a mean arterial pressure (MAP) of 65 mm Hg in patients with acute liver failure or acute on chronic liver failure over other fluids, especially when serum albumin is low (<3mg/dL), with concomitant assessment of perfusion.
Quality of Evidence: Low
We suggest placing an arterial catheter for blood pressure monitoring in patients with acute liver failure or acute on chronic liver failure and shock.
Quality of Evidence: Low
We suggest using invasive hemodynamic monitoring to guide therapy in patients with acute liver failure or acute on chronic liver failure and clinically impaired perfusion.
Quality of Evidence: Low
We recommend using norepinephrine as a first-line vasopressor in patients with acute liver failure or acute on chronic liver failure who remain hypotensive despite fluid resuscitation, or those with profound hypotension and tissue hypoperfusion even if fluid resuscitation is ongoing.
Quality of Evidence: Moderate
We suggest adding low-dose vasopressin to norepinephrine in patients with acute liver failure or acute on chronic liver failure who remain hypotensive despite fluid resuscitation to increase blood pressure.
Quality of Evidence: Low
We suggest using viscoelastic testing (thromboelastography/rotational thromboelastometry [ROTEM]) over measuring international normalized ratio (INR), platelet, and fibrinogen in critically ill patients with acute liver failure or acute on chronic liver failure.
Quality of Evidence: Low
We suggest using a transfusion threshold of 7 mg/dL, over other thresholds, for critically ill patients with acute liver failure or acute on chronic liver failure.
Quality of Evidence: Low
We suggest using low molecular weight heparin (LMWH) or vitamin K antagonists, over no anticoagulation, in patients with portal venous thrombosis or pulmonary embolus.
Quality of Evidence: Very Low
We suggest using low molecular weight heparin over pneumatic compression stockings for venous thromboembolism prophylaxis in hospitalized patients withacute on chronic liver failure.
Quality of Evidence: Low
We recommend viscoelastic testing (thromboelastography/ROTEM), over measuring INR, platelet, fibrinogen, in critically ill patients with acute liver failure or acute on chronic liver failure undergoing procedures.
Quality of Evidence: Moderate
We recommend against using Eltrombopag in acute on chronic liver failure patients with thrombocytopenia prior to surgery/invasive procedures.
Quality of Evidence: Low
We suggest using a low tidal volume strategy over high tidal volume strategy in patients with acute liver failure or acute on chronic liver failure and acute respiratory distress syndrome.
Quality of Evidence: Low
We suggest against using high PEEP, over low PEEP, in patients with acute liver failure or acute on chronic liver failure and acute respiratory distress syndrome.
Quality of Evidence: Low
We suggest treating portopulmonary hypertension (POPH) with agents approved for pulmonary arterial hypertension (PAH) in patients with mean pulmonary artery pressure greater than 35mm Hg.
Quality of Evidence: Very Low
We recommend supportive care with supplemental oxygen in the treatment of hepatopulmonary syndrome (HPS), pending possible liver transplantation.
We recommend placing chest tube with an attempt to pleurodesis for hepatic hydrothorax in patients in whom transjugular intrahepatic portosystemic shunt (TIPS) is not an option or as a palliative intent.
We suggest using high-flow nasal cannula (HFNC) over noninvasive ventilation in hypoxic critically ill patients with acute liver failure or acute on chronic liver failure.
Quality of Evidence: Low
We suggest using RRT early in patients with ALF and AKI.
Quality of Evidence: Very Low
We recommend using vasopressors, over not using vasopressors, in critically ill patients with acute on chronic liver failure who develop hepatorenal syndrome (HRS).
Quality of Evidence: Moderate
We recommend targeting a serum blood glucose of 110-180 mg/dL in patients with acute liver failure or acute on chronic liver failure.
Quality of Evidence: Moderate
We suggest using stress-dose glucocorticoids in the treatment of septic shock in patients with acute liver failure or acute on chronic liver failure.
Quality of Evidence: Low
We suggest against using a low protein goal in patients with acute liver failure or acute on chronic liver failure, but rather targeting protein goals comparable with critically ill patients without liver failure (1.2– 2.0g protein/kg dry or ideal body weight per day [IBW/d]).
Quality of Evidence: Very Low
We suggest not using branched-chain amino acids (BCAAs) in critically ill patients hospitalized with acute liver failure or acute on chronic liver failure who are tolerating enteral medications.
Quality of Evidence: Very Low
We suggest enteral nutrition (EN) over parenteral nutrition (PN) in critically ill patients hospitalized withacute liver failure or acute on chronic liver failure without contraindication for enteral feeding.
Quality of Evidence: Low
We recommend screening patients with acute liver failure or acute on chronic liver failure for drug-induced causes of liver failure. Drug that are proven or highly suspected to be the cause of acute liver failure or acute on chronic liver failure should be discontinued.
In patients with acute liver failure or acute on chronic liver failure, we recommend adjusting the doses of medications that undergo hepatic metabolism based on the patient’s residual hepatic function and using the best available literature. When available, a clinical pharmacist should be consulted.
A complete list of the guidelines authors and contributors is available within the published manuscript.